| 张宇晶 董敏 平超强 赵红丽 孔德胜 洪珞珈.自体DC、CIK细胞在急性髓细胞白血病治疗中的研究进展[J].,2015,15(4):760-764 |
| 自体DC、CIK细胞在急性髓细胞白血病治疗中的研究进展 |
| The Research Progress of Autologous DC and CIK Cells in the Treatmentof Acute Myeloid Leukemia |
| |
| DOI： |
| 中文关键词: 树突状细胞（DC） 细胞因子诱导的杀伤细胞（CIK） 免疫疗法 急性髓细胞白血病 |
| 英文关键词: Dendritic cells Cytokine-induced killer cells Immunotherapy Acute myeloid leukemia |
| 基金项目:黑龙江省留学归国人员基金（LC08C24）；黑龙江省科技厅课题（QC2012C050）；黑龙江省青年科学基金项目（QC2012C050） |
|
| 摘要点击次数: 815 |
| 全文下载次数: 0 |
| 中文摘要: |
| 树突状细胞（DC）是初级免疫应答的激发者，是最有活力的抗原递呈细胞（APC），可以有效地抑制白血病细胞逃逸。未成熟
DC 细胞从细胞外捕获各种抗原信息，成熟DC 细胞传递各种抗原信息给宿主淋巴结的T细胞，激活抗原相关的主要组织相容性
复合体（MHC）限制性特异性免疫应答，另外，亦可通过影响B细胞的增殖，不同程度的活化体液免疫应答。细胞因子诱导的杀伤
细胞（CIK）是一组具有细胞毒作用的异质细胞群，是较LAK细胞溶瘤活性更强的一种免疫活性细胞，对包括白血病在内的多种
恶性肿瘤具有抗肿瘤效应，具有非MHC限制性的杀瘤特点。二者联合培养及应用又增强了各自的活性。DC细胞与CIK 细胞对
于白血病的疗效不仅在实验室得以证实，而且已经逐步应用于临床，其在清除微小残留病以及预防造血干细胞移植后复发中取
得了良好的效果。随着细胞制备技术的完善和研究的进一步深入，自体DC、CIK 细胞治疗急性髓细胞白血病逐渐获得众多专家
的认可。中国卫生部已经把自体免疫细胞治疗技术做为第三类医疗技术应用于临床，批准号200984。本文就目前DC、CIK、
DC-CIK 细胞免疫疗法在急性髓细胞白血病中的应用进展加以综述。 |
| 英文摘要: |
| Dendritic cells (DC) are the excitation of the primary immune response and antigen-presenting cells of the most
energetic, they can inhibit escape of leukemia cells effectively. Immature DC capture various of antigens from the extracellular, and
mature DC pass them to the T cells of host node, then, activate antigens associated major histocompatibility complex (MHC)-restricted
specific immune response. Further, they can also activate humoral immune responses in different degrees by affecting the proliferation of
the B cells. Cytokine-induced killer (CIK) cells are a group of heterogeneous cell populations with cytotoxic effect, and they are a kind of
immune cells that can dissolve tumor better than LAK cells, with which non-restricted anti-tumor effect, they can kill a variety of
malignancies, including leukemia. The combination of culture and application enhance their activity respectively. The efficacy of DC and
CIK for leukemia has not only been confirmed in the laboratory, but also has been gradually applied to clinical. It has achieved good
efficacy on clearing minimal residual disease and preventing relapse after the hematopoietic stem cell transplantation. With the improve
of cell preparation techniques and further research, the method of autologous DC and CIK treat on acute myeloid leukemia patients has
gradually gained the recognition of many experts. The autoimmune cell therapy technology has been used in clinical by Chinese Ministry
of Health as a Class III medical technology, Grant No. 200984. This article summarizs the application progress of DC and CIK cell
immunotherapy in acute myeloid leukemia. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
